Long-term solutions: Building resilience into the drug supply to prevent shortages
Dec, 20 2025
Every year, hundreds of life-saving drugs disappear from hospital shelves. Not because they’re out of style or no longer needed-but because the system that makes and moves them is brittle. In 2022, the FDA recorded 245 drug shortages, with over half involving sterile injectables used in emergency rooms, ICUs, and during surgery. These aren’t minor inconveniences. They’re emergencies. Patients get delayed treatments. Clinicians improvise with less effective alternatives. Hospitals pay up to $216 million extra annually just to cope. And the root cause? A supply chain built for efficiency, not survival.
Why the drug supply chain broke
For decades, pharmaceutical companies chased lower costs. They moved manufacturing overseas, especially to China and India, where production was cheaper and faster. By 2023, 72% of active pharmaceutical ingredients (APIs)-the core chemical components of medicines-were made outside the U.S. Nearly 30% came from just two countries. This worked fine when global trade was smooth. But when the pandemic hit, borders closed, shipping slowed, and factories shut down. Suddenly, the lean, just-in-time model looked like a liability. The problem wasn’t just geography. It was secrecy. Most companies only knew their direct suppliers (Tier 1). Fewer than 1 in 8 had visibility into who supplied the raw materials three steps back (Tier 3). If a single chemical plant in India had a power outage, the ripple effect could hit hospitals in Ohio, Texas, or Perth. And no one saw it coming.What resilience actually means
Resilience isn’t about having backup plans. It’s about designing the system so it doesn’t break in the first place. The National Academies of Sciences laid out a clear framework: anticipation, planning, and risk mitigation-in that order. The most cost-effective move? Giving everyone in the chain better information. Knowing what’s at risk, where it’s made, and how long it takes to replace is 37% more efficient than just stockpiling or scrambling after a shortage hits. That means mapping the entire supply chain-from the mine that produces a mineral used in an antibiotic, to the factory that synthesizes the API, to the warehouse that ships it to your local pharmacy. Right now, only 35% of companies can do this fully. The rest are flying blind.Four proven strategies to build resilience
There’s no single fix. But four strategies, used together, make a real difference.- Supplier diversification: Don’t rely on one source. For every critical drug, have at least three suppliers spread across different continents. One in China, one in Europe, one in the U.S. That way, if one goes down, the others can pick up the slack.
- Manufacturing redundancy: For the most essential medicines-like epinephrine, insulin, or antibiotics-duplicate production. If 80% of your API volume comes from one plant, build a second one, even if it’s more expensive. The cost of a shortage is far higher.
- Buffer stockpiling: Keep 6 to 12 months of supply for critical injectables. It sounds expensive, but it’s cheaper than emergency air freight, overtime pay for nurses, or lawsuits from delayed care. The catch? You can’t stockpile everything. Prioritize based on risk, not just clinical importance.
- Substitution capacity: Have at least 15% of your formulary made up of alternative versions of key drugs. If one brand of vancomycin runs out, another one with the same effect should be ready to use. This isn’t about generics-it’s about pre-approved, clinically equivalent options that regulators have already cleared.
Domestic production vs. global diversification
A lot of people say: “Just bring manufacturing back to the U.S.” That’s appealing. But reshoring API production adds 25-40% to costs. That’s not sustainable for most drugs. You don’t need to make every pill at home. You need to make the right pills at home. The smarter approach? A hybrid model. Build domestic capacity for the top 50 most critical, most vulnerable drugs-like those used in cancer treatment or during cardiac arrest. For everything else, diversify internationally. A Duke-Margolis study found this combo prevents 85% of critical shortages at a cost of $1.2-1.8 billion per year. Just stockpiling everything? That costs $3.5-4.2 billion and only stops 45% of shortages.The hidden threat: Cyberattacks
You can have the best suppliers, the biggest stockpiles, and the most advanced factories-but if a hacker shuts down your logistics software, you’re still in trouble. Between 2020 and 2023, cyberattacks on healthcare supply chains jumped 214%. One ransomware attack can freeze shipments for days. That’s why cybersecurity isn’t an IT issue-it’s a drug access issue. Companies now need to follow the NIST Cybersecurity Framework across all partners, not just their own systems. That means vendors, freight carriers, even third-party warehouses must meet minimum security standards. The Healthcare Distribution Alliance found that public-private threat-sharing networks cut response times by 47%. That’s not optional anymore.Technology is changing the game
AI is no longer science fiction in pharma supply chains. In 2021, only 22% of companies used AI for demand forecasting. By 2023, that number hit 58%. Pfizer used AI across 150 distribution centers and cut stockouts by 38%. The system doesn’t just predict how much you’ll need-it learns from weather patterns, geopolitical events, and even social media trends about disease outbreaks. Supply chain mapping tools now use blockchain and real-time sensors to track drugs from raw material to patient. Companies that invested in these tools saw 32% fewer disruptions-even though they spent only 8% of their resilience budget on them. The return on investment is clear: visibility prevents chaos.
What’s changing in policy
The government is finally stepping in. In 2024, the HHS launched a $520 million plan to boost domestic production of 50 critical medicines, aiming for 40% API sourcing from U.S. soil by 2027. The FDA now requires manufacturers to conduct annual vulnerability assessments-enforced starting in Q3 2025. And by 2026, Medicare will start tying reimbursement to supply chain transparency. If you can’t show where your drugs come from, you won’t get paid. The European Union is doing the same. Over 60% of global pharma companies now run parallel supply chains for the U.S. and EU markets. That’s not coincidence. It’s adaptation.Why some efforts fail
Many companies try to build resilience but stumble. Why? Three reasons:- Data doesn’t talk: 78% of companies use different systems across suppliers. No one can see the full picture.
- No one’s trained: Only 35% of teams have staff who understand supply chain risk analytics. Most are still using spreadsheets from 2010.
- Price wins every time: Hospitals and insurers still pick the cheapest drug, even if it comes from a single, risky source. Manufacturers can’t invest in resilience if buyers won’t pay for it.
The human cost of inaction
Behind every shortage is a patient. A child waiting for antibiotics. An elderly person skipping insulin doses. A cancer patient whose chemo is delayed because the IV bag isn’t available. Dr. Scott Gottlieb, former FDA commissioner, put it bluntly: “No single policy lever will fix this.” We can’t just react. We have to build. Not just more factories. Not just bigger stockpiles. But smarter systems. Systems that anticipate failure before it happens. Systems that give every pharmacist, nurse, and doctor confidence that the next drug they need will be there. The cost of doing nothing? Billions in waste. Thousands of disrupted lives. And a system that still breaks every time the world shakes.The time to act isn’t after the next crisis. It’s now.
What causes most drug shortages today?
Most shortages today stem from supply chain fragility-not lack of demand. Over 60% are linked to manufacturing issues, especially at single-source facilities overseas. Natural disasters, regulatory delays, quality control failures, and cyberattacks are common triggers. The biggest risk is geographic concentration: too many critical APIs made in just a few countries.
Is stockpiling drugs a good long-term solution?
Stockpiling helps in the short term, but it’s not a full solution. Keeping 6-12 months of critical injectables on hand prevents 45% of shortages. But it’s expensive-$3.5-4.2 billion a year-and doesn’t fix the root problem. The best approach combines smart stockpiling with supplier diversification, manufacturing redundancy, and better forecasting.
Why isn’t more drug manufacturing done in the U.S.?
It’s expensive. Bringing API production back to the U.S. raises costs by 25-40%. Many companies avoid it because buyers-hospitals, insurers, and government programs-still prioritize low price over supply security. Without policy changes that reward resilience, manufacturers can’t justify the investment.
How does AI help prevent drug shortages?
AI analyzes data from suppliers, weather, shipping delays, disease trends, and even political events to predict disruptions before they happen. Companies using AI for demand forecasting report up to 38% fewer stockouts. It’s not magic-it’s pattern recognition. AI spots risks humans miss, like a chemical plant in India shutting down after a monsoon, weeks before it affects U.S. hospitals.
What’s the biggest barrier to fixing the drug supply chain?
The biggest barrier is misaligned incentives. Buyers pay for the lowest price, not the most reliable source. Manufacturers can’t afford to invest in resilience if they’re punished for higher costs. Until reimbursement models change to reward transparency and redundancy, progress will be slow.
Are generic drugs more vulnerable to shortages?
Yes. Generic drugs are often made by a single manufacturer with thin profit margins. There’s little incentive to invest in backup suppliers or redundant facilities. In fact, 62% of 2022 shortages involved generics, especially sterile injectables. These drugs are essential but economically fragile.
How can hospitals prepare for shortages today?
Hospitals should create a priority list of critical drugs, identify approved alternatives, and maintain small emergency stockpiles. They should also join regional sharing networks and work with distributors who use real-time supply tracking. Most importantly, they need to stop automatically choosing the cheapest option-ask where the drug comes from and how secure the supply is.
Will new regulations fix the problem?
Regulations like the FDA’s 2025 vulnerability assessment rule and Medicare’s 2026 transparency requirement are necessary steps. But they’re only effective if enforced and paired with financial incentives. Rules without rewards won’t change behavior. Companies need to see a return on investment in resilience-or they won’t make the changes.
Meina Taiwo
December 20, 2025 AT 16:51Siobhan K.
December 21, 2025 AT 23:56Jerry Peterson
December 22, 2025 AT 04:22Jon Paramore
December 24, 2025 AT 02:38Swapneel Mehta
December 24, 2025 AT 04:10Brian Furnell
December 24, 2025 AT 15:06Grace Rehman
December 25, 2025 AT 18:26Cameron Hoover
December 27, 2025 AT 07:38mukesh matav
December 27, 2025 AT 09:09Theo Newbold
December 27, 2025 AT 17:21Jay lawch
December 28, 2025 AT 01:47Jackie Be
December 29, 2025 AT 12:23Peggy Adams
December 30, 2025 AT 22:13Erika Putri Aldana
January 1, 2026 AT 07:44Orlando Marquez Jr
January 1, 2026 AT 09:11